Cathie Wood’s ARK sells Twist Bioscience and buys Circle Internet stock

ARK purchased 161,513 shares of Circle Internet Group (CRCL) for $20.45M and sold 190,100 shares of Twist Bioscience (TWST) for $8.46M, indicating accumulation in Circle and trimming of Twist. Other notable sells: Roku (44,640? reported 54,640) for $5.34M, Teradyne 18,620 shares for $5.66M, Bullish (BLSH) across ETFs for $1.62M, and smaller disposals including TSM ($1.07M) and Veracyte ($1.50M). ARK added 22,538 shares of 10X Genomics (TXG) for $431k, signifying a modest rotation toward certain tech/biotech names and continued active repositioning across the portfolio.

Analysis

ARK’s continued rotation into select crypto infrastructure and genomic-tool names is acting less like a pure conviction call and more like a flow-driven re-rating mechanism for small- to mid-cap innovation stocks. When an ETF with concentrated, visibility-driven flows accumulates a name, it compresses natural liquidity and amplifies headline sensitivity — meaning regulatory nuances around stablecoins or a single positive institutional announcement can produce outsized short-term moves in CRCL.

The simultaneous trimming of synthetic-biology and ad/consumer-tech exposures signals a tactical de-risking rather than a sector repudiation: ARK is reallocating from higher-beta cash-flow-dependent stories to platform/service providers with clearer TAM expansion vectors. That second-order effect pressures peers with similar business models (DNA synthesis providers, ad-supported streaming platforms), increasing the chance of dispersion within the groups as investors re-evaluate durable revenue vs. growth optionality.

Catalysts to watch are near-term earnings cadence, regulatory guidance on stablecoins/crypto custody, and order-book/consumption metrics for genomic instruments; these can reverse positioning quickly over days to weeks. For 3–12 month horizons, the trade is between ETF-driven momentum (short-term) and fundamental adoption curves (medium-term); a failure in adoption or a regulatory hit would be the fastest path to unwind the recent re-rating.

Key Decisions for Investors

• Long CRCL, tactical options-backed position: buy a 3-month call spread sized to risk 1% NAV (delta ~0.40 buy / delta ~0.60 sell). Rationale: capture ETF-driven re-rating and any positive regulatory/partner announcements. Target 30–50% upside; max loss = premium (~1% NAV). Stop if CRCL falls 15% from entry on volume-confirmed break.
• Paired trade — long TXG / short TWST (equal notional, 0.75–1.0% NAV each): capitalizes on rotation into genomic tools vs. de-risking of synthetic biology. Time horizon 3–9 months. Risk/reward: target 40%+ on TXG leg vs 30% downside on TWST; tighten stops if TWST shows reversal in order-book metrics or TXG misses instrument-sales cadence.
• Short BLSH as a hedge against a crypto custody/venue rotation: use 3–6 month OTM put position sized to 0.5% NAV with a companion hedge via small long CRCL exposure. This profits if flows favor issuer/platform over exchange tokens. Take profits on 25–35% move; cut if broader crypto spot market rallies >20% in 2 weeks.
• Avoid directional large ROKU/TER positions; instead use contingent pairs: sell covered-call against a small core long in high-quality ad/automation names if advertising-economic indicators slip. Horizon: 1–3 months; target to harvest 3–8% premium while keeping downside protection intact.